InSphero at SBI2 Annual Meeting 2024
Join us at SBI2 Annual Meeting 2024 in Boston, and learn from experts in biological imaging and screening to shape the future of biomedical research.
Explore our activities during SBI2 2024 in Boston from Wednesday, September 18 to Friday, September 20. Don’t miss the chance to connect with pioneers and innovators driving the next generation of scientific discovery!
Quick navigation
Meet our Team at SBI2 Annual Meeting 2024


Judi Wardwell-Swanson
Senior Scientist Consultant
Judi Wardwell-Swanson
Senior Scientist Consultant
Judi Wardwell-Swanson is a Senior Scientist consultant at InSphero and past-president of the Society of Biomolecular Imaging and Informatics (SBI2) board of directors. At InSphero her work is focused on the development of high content imaging applications utilizing 3D human microtissue models. Judi also has accumulated more than 25 years of experience in the pharma industry and has a long-standing interest in the utilization of genomics and imaging technologies to help drive drug discovery. During her tenure at Bristol-Myers Squibb, her team conducted phenotypic screens in physiologically-relevant cell models with an emphasis on the identification and validation new drug targets using a variety of genomics and chemical biology approaches. Judi is also the author of several journal articles and a book chapter on high content imaging-related topics such as HCS data management, analysis of multidimensional imaging data, and 3D imaging/analysis of multicellular spheroids and micro-tissue models.




Ozlem Yavas Grining, PhD
Senior Scientist, Technology and Platforms
Ozlem Yavas Grining, PhD
Senior Scientist, Technology and Platforms
Özlem is a Senior Scientist at InSphero with a Ph.D. in Physics and over 10 years of experience in multidisciplinary research spanning cell biology, microfluidics, automation, and imaging. At InSphero, she focuses on developing high-content imaging assays and 3D image analysis pipelines for spheroid-based drug discovery applications. While focusing on technology development and HCI endpoints, she is also keen on improving process efficiency through automation. Her background in both engineering and life sciences allows her to contribute to various aspects of preclinical research and technology development in drug discovery.


Exhibitor Spotlight
Resolving compound mechanism through phenotypic analysis of morphologic features in a 3D liver steatosis model
Date: Thursday, 19 September, 2024 | 4:00 - 4:15


Ozlem Yavas Grining, PhD
Senior Scientist, Technology and Platforms
Ozlem Yavas Grining, PhD
Senior Scientist, Technology and Platforms
Özlem is a Senior Scientist at InSphero with a Ph.D. in Physics and over 10 years of experience in multidisciplinary research spanning cell biology, microfluidics, automation, and imaging. At InSphero, she focuses on developing high-content imaging assays and 3D image analysis pipelines for spheroid-based drug discovery applications. While focusing on technology development and HCI endpoints, she is also keen on improving process efficiency through automation. Her background in both engineering and life sciences allows her to contribute to various aspects of preclinical research and technology development in drug discovery.


Poster Presentation
Improving Predictivity and Adding Mechanistic Insight to Liver Safety Assessment: Combining human Microtissue Models with Multiparametric Readouts
Date: Thursday, 19 September, 2024 | 4:45 - 7:00 PM
Poster number: 30


Judi Wardwell-Swanson
Senior Scientist Consultant
Judi Wardwell-Swanson
Senior Scientist Consultant
Judi Wardwell-Swanson is a Senior Scientist consultant at InSphero and past-president of the Society of Biomolecular Imaging and Informatics (SBI2) board of directors. At InSphero her work is focused on the development of high content imaging applications utilizing 3D human microtissue models. Judi also has accumulated more than 25 years of experience in the pharma industry and has a long-standing interest in the utilization of genomics and imaging technologies to help drive drug discovery. During her tenure at Bristol-Myers Squibb, her team conducted phenotypic screens in physiologically-relevant cell models with an emphasis on the identification and validation new drug targets using a variety of genomics and chemical biology approaches. Judi is also the author of several journal articles and a book chapter on high content imaging-related topics such as HCS data management, analysis of multidimensional imaging data, and 3D imaging/analysis of multicellular spheroids and micro-tissue models.

